Understanding the Burden of Chemotherapy-Induced Myelosuppression in Extensive-Stage Small Cell Lung Cancer

Megan May, PharmD, opens the program by introducing the multidisciplinary panel and outlining the discussion, which focuses on the burden of chemotherapy-induced myelosuppression (CIM) in extensive-stage small cell lung cancer (ES-SCLC), the rationale for proactive myeloprotection, and practical strategies for integrating supportive care into routine clinical practice. Taylor Praska, PharmD, explains that CIM can lead to chemotherapy dose reductions, delays, and interruptions that may compromise treatment delivery while increasing the risk of serious complications, including infection, bleeding, hospitalization, and greater healthcare resource utilization. Amanda Edmond, PA-C, expands on the patient-centered impact of CIM, emphasizing the physical, emotional, logistical, and financial challenges associated with managing treatment-related hematologic toxicities. Together, the panel establishes the significant clinical burden of myelosuppression in ES-SCLC and underscores the importance of effective supportive care strategies to maintain treatment continuity, optimize patient outcomes, and improve the overall treatment experience.